Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial

G. D. Batty; Q. Li; R. Huxley; S. Zoungas; B. A. Taylor; B. Neal; B. de Galan; M. Woodward; S. B. Harrap; S. Colagiuri; A. Patel; J. Chalmers

doi:10.1016/j.eurpsy.2011.07.005

Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial

G. D. Batty
, Q. Li
, R. Huxley
, S. Zoungas
, B. A. Taylor
, B. Neal
, B. de Galan
, M. Woodward
, S. B. Harrap
, S. Colagiuri
, A. Patel
, J. Chalmers

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Objective: Examine the association of oral disease with future dementia/cognitive decline in a cohort of people with type 2 diabetes. Methods: A total of 11,140 men and women aged 55-88 years at study induction with type 2 diabetes participated in a baseline medical examination when they reported the number of natural teeth and days of bleeding gums. Dementia and cognitive decline were ascertained periodically during a 5-year follow-up. Results: Relative to the group with the greatest number of teeth (more than or equal to 22), having no teeth was associated with the highest risk of both dementia (hazard ratio; 95% confidence interval: 1.48; 1.24, 1.78) and cognitive decline (1.39; 1.21, 1.59). Number of days of bleeding gums was unrelated to these outcomes. Conclusions: Tooth loss was associated with an increased risk of both dementia and cognitive decline.

Original language	English (US)
Pages (from-to)	49-52
Number of pages	4
Journal	European Psychiatry
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.eurpsy.2011.07.005
State	Published - Jan 2013
Externally published	Yes

Keywords

Cognitive decline
Cohort study
Dementia
Oral disease

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1016/j.eurpsy.2011.07.005

Fingerprint

Dive into the research topics of 'Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial'. Together they form a unique fingerprint.

Cite this

Batty, G. D., Li, Q., Huxley, R., Zoungas, S., Taylor, B. A., Neal, B., de Galan, B., Woodward, M., Harrap, S. B., Colagiuri, S., Patel, A., & Chalmers, J. (2013). Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry, 28(1), 49-52. https://doi.org/10.1016/j.eurpsy.2011.07.005

Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. / Batty, G. D.; Li, Q.; Huxley, R. et al.
In: European Psychiatry, Vol. 28, No. 1, 01.2013, p. 49-52.

Research output: Contribution to journal › Article › peer-review

Batty, GD, Li, Q, Huxley, R, Zoungas, S, Taylor, BA, Neal, B, de Galan, B, Woodward, M, Harrap, SB, Colagiuri, S, Patel, A & Chalmers, J 2013, 'Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial', European Psychiatry, vol. 28, no. 1, pp. 49-52. https://doi.org/10.1016/j.eurpsy.2011.07.005

Batty GD, Li Q, Huxley R, Zoungas S, Taylor BA, Neal B et al. Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. European Psychiatry. 2013 Jan;28(1):49-52. doi: 10.1016/j.eurpsy.2011.07.005

@article{2816e43524534780a1b536c62d8696ae,

title = "Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial",

abstract = "Objective: Examine the association of oral disease with future dementia/cognitive decline in a cohort of people with type 2 diabetes. Methods: A total of 11,140 men and women aged 55-88 years at study induction with type 2 diabetes participated in a baseline medical examination when they reported the number of natural teeth and days of bleeding gums. Dementia and cognitive decline were ascertained periodically during a 5-year follow-up. Results: Relative to the group with the greatest number of teeth (more than or equal to 22), having no teeth was associated with the highest risk of both dementia (hazard ratio; 95\% confidence interval: 1.48; 1.24, 1.78) and cognitive decline (1.39; 1.21, 1.59). Number of days of bleeding gums was unrelated to these outcomes. Conclusions: Tooth loss was associated with an increased risk of both dementia and cognitive decline.",

keywords = "Cognitive decline, Cohort study, Dementia, Oral disease",

author = "Batty, \{G. D.\} and Q. Li and R. Huxley and S. Zoungas and Taylor, \{B. A.\} and B. Neal and \{de Galan\}, B. and M. Woodward and Harrap, \{S. B.\} and S. Colagiuri and A. Patel and J. Chalmers",

note = "Funding Information: The ADVANCE trial was funded by grants from Servier and the National Health and Medical Research Council of Australia. These sponsors had no role in the design of the study, data collection, data analysis, data interpretation, and the writing of the manuscript. Study data were not made available to the sponsors. The Management Committee, whose membership did not include any sponsor representatives, had final responsibility for the decision to submit this manuscript for publication. The authors had full access to the study data and take responsibility for the accuracy of the analysis. David Batty is a welcome trust career development fellow. The Medical Research Council (MRC) Social and Public Health Sciences Unit receives funding from the UK MRC and the Chief Scientist Office at the Scottish Government Health Directorates. The Centre for Cognitive Ageing and Cognitive Epidemiology is supported by the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Medical Research Council, and the University of Edinburgh as part of the cross-council lifelong health and well-being initiative.",

year = "2013",

month = jan,

doi = "10.1016/j.eurpsy.2011.07.005",

language = "English (US)",

volume = "28",

pages = "49--52",

journal = "European Psychiatry",

issn = "0924-9338",

publisher = "Cambridge University Press",

number = "1",

}

TY - JOUR

T1 - Oral disease in relation to future risk of dementia and cognitive decline

T2 - Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial

AU - Batty, G. D.

AU - Li, Q.

AU - Huxley, R.

AU - Zoungas, S.

AU - Taylor, B. A.

AU - Neal, B.

AU - de Galan, B.

AU - Woodward, M.

AU - Harrap, S. B.

AU - Colagiuri, S.

AU - Patel, A.

AU - Chalmers, J.

N1 - Funding Information: The ADVANCE trial was funded by grants from Servier and the National Health and Medical Research Council of Australia. These sponsors had no role in the design of the study, data collection, data analysis, data interpretation, and the writing of the manuscript. Study data were not made available to the sponsors. The Management Committee, whose membership did not include any sponsor representatives, had final responsibility for the decision to submit this manuscript for publication. The authors had full access to the study data and take responsibility for the accuracy of the analysis. David Batty is a welcome trust career development fellow. The Medical Research Council (MRC) Social and Public Health Sciences Unit receives funding from the UK MRC and the Chief Scientist Office at the Scottish Government Health Directorates. The Centre for Cognitive Ageing and Cognitive Epidemiology is supported by the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Medical Research Council, and the University of Edinburgh as part of the cross-council lifelong health and well-being initiative.

PY - 2013/1

Y1 - 2013/1

N2 - Objective: Examine the association of oral disease with future dementia/cognitive decline in a cohort of people with type 2 diabetes. Methods: A total of 11,140 men and women aged 55-88 years at study induction with type 2 diabetes participated in a baseline medical examination when they reported the number of natural teeth and days of bleeding gums. Dementia and cognitive decline were ascertained periodically during a 5-year follow-up. Results: Relative to the group with the greatest number of teeth (more than or equal to 22), having no teeth was associated with the highest risk of both dementia (hazard ratio; 95% confidence interval: 1.48; 1.24, 1.78) and cognitive decline (1.39; 1.21, 1.59). Number of days of bleeding gums was unrelated to these outcomes. Conclusions: Tooth loss was associated with an increased risk of both dementia and cognitive decline.

AB - Objective: Examine the association of oral disease with future dementia/cognitive decline in a cohort of people with type 2 diabetes. Methods: A total of 11,140 men and women aged 55-88 years at study induction with type 2 diabetes participated in a baseline medical examination when they reported the number of natural teeth and days of bleeding gums. Dementia and cognitive decline were ascertained periodically during a 5-year follow-up. Results: Relative to the group with the greatest number of teeth (more than or equal to 22), having no teeth was associated with the highest risk of both dementia (hazard ratio; 95% confidence interval: 1.48; 1.24, 1.78) and cognitive decline (1.39; 1.21, 1.59). Number of days of bleeding gums was unrelated to these outcomes. Conclusions: Tooth loss was associated with an increased risk of both dementia and cognitive decline.

KW - Cognitive decline

KW - Cohort study

KW - Dementia

KW - Oral disease

UR - https://www.scopus.com/pages/publications/84872425950

UR - https://www.scopus.com/pages/publications/84872425950#tab=citedBy

U2 - 10.1016/j.eurpsy.2011.07.005

DO - 10.1016/j.eurpsy.2011.07.005

M3 - Article

C2 - 21964484

AN - SCOPUS:84872425950

SN - 0924-9338

VL - 28

SP - 49

EP - 52

JO - European Psychiatry

JF - European Psychiatry

IS - 1

ER -

Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this